Saturday 17 October 2026
Export MDXH’s income statement to Excel — free account
MDxHealth SA
MDXH Healthcare Diagnostics & Research
MDxHealth SA’s revenue for fiscal 2025 (year ended December 2025) was $107.9 million, up 19.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS fell 15.8%, free cash flow fell 200.2% and total debt rose 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
0.21
0.39
−65.00%
Follow MDXH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.33 | 1.63 | 1.07 | 0.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
140.07 | 471.87 | (80.41) | (3.67) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.88 | 2.14 | 1.62 | 0.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(50.46) | (106.99) | (172.65) | (20.09) | |
EV/FCF |
(36.08) | (54.25) | (59.13) | (15.24) | |
Quick Ratio |
0.98 | 0.88 | 1.38 | 0.91 | |
Current Ratio |
1.14 | 1.08 | 1.63 | 1.15 | |
Net Debt/EBITDA |
(138.99) | (17.30) | (12.41) | (31.34) | |
Debt/Assets |
55.71% | 57.25% | 64.75% | 78.77% | |
Debt/Equity |
(10.40) | (7.00) | (5.15) | (3.42) | |
Asset Turnover |
0.64 | 0.72 | 0.67 | 0.84 | |
Operating CF/Net income |
(0.21) | (0.04) | 0.17 | 0.51 | |
Capex/Depreciation |
(0.12) | (0.02) | (0.15) | (0.02) | |
Interest Coverage |
(0.45) | (1.01) | (0.82) | (0.84) | |
Research and Development Expense of Revenue |
7.32% | 12.17% | 7.79% | 7.33% | |
Selling, General and Administrative Expense of Revenue |
65.79% | 63.54% | 74.91% | 72.03% | |
Intangible Assets out of Total Assets |
0.51 | 0.53 | 0.48 | 0.58 | |
Share Based Compensation of Revenue |
1.63% | 2.12% | 2.05% | 2.22% | |
Graham Net Nets |
(0.45) | (0.60) | (0.94) | (5.56) | |
Graham Number |
1.82 | 1.90 | 2.45 | 3.07 | |
Earnings Yield |
(19.14%) | (18.49%) | (30.00%) | (175.61%) | |
Free Cash Flow Yield |
(3.42%) | (2.42%) | (2.55%) | (32.52%) | |
Revenue per Share |
0.55 | 0.66 | 0.53 | 0.52 | |
Operating CF per Share |
0.03 | 0.01 | (0.03) | (0.11) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.03 | 0.01 | (0.04) | (0.11) | |
Cash per Share |
0.64 | 0.58 | 0.83 | 0.37 | |
Shareholders Equity per Share |
(0.17) | (0.24) | (0.39) | (0.58) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.17) | (0.24) | (0.39) | (0.58) | |
Free Cash Flow |
1.40 | 0.32 | (1.85) | (5.89) | |
Working Capital |
7.06 | 3.88 | 26.32 | 5.63 | |
Capital Expenditures |
(0.26) | (0.05) | (0.36) | (0.04) | |
Net Current Asset Value |
(104.32) | (106.64) | (113.17) | (119.46) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.62 | 14.56 | 14.90 | 15.32 | |
Average Payables |
9.89 | 9.17 | 9.81 | 8.65 | |
Average Inventory |
5.23 | 5.31 | 5.35 | 5.05 | |
Average Assets |
155.84 | 152.64 | 167.83 | 136.36 | |
Average Common Equity |
4.37 | 1.37 | (7.13) | (15.64) |
Columns are period end dates